



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/485, 9/00, 9/16 A61K 47/36	A1	(11) International Publication Number: WO 93/15737 (43) International Publication Date: 19 August 1993 (19.08.93)
(21) International Application Number: PCT/GB93/00228 (22) International Filing Date: 4 February 1993 (04.02.93) (30) Priority data: 9202464.5 5 February 1992 (05.02.92) GB (71) Applicant (for all designated States except US): DANBIO-SYST UK LIMITED [GB/GB]; 6 William Lee Buildings, Highfields Science Park, Nottingham NG7 2RQ (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : ILLUM, Lisbeth [DK/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB).		(74) Agent: BASSETT, Richard, S.; Eric Potter Clarkson, St Mary's Court, St Mary's Gate, Nottingham NG1 1LE (GB). (81) Designated States: AU, CA, FI, GB, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: COMPOSITIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLITES OF OPIOID ANALGESICS (57) Abstract A composition for nasal administration of polar metabolites of opioid analgesics comprises a polar metabolite of an opioid analgesic and an absorption promoting agent. Preferred metabolites morphine-6-glucuronide and morphine-6-sulphate. A preferred absorption promoting agent is chitosan but other suitable agents include cationic polymers, bioadhesive agents, surface active agents, fatty acids, chelating agents, mucolytic agents, cyclodextrin, microsphere preparations or combinations thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

COMPOSITIONS FOR NASAL ADMINISTRATION CONTAINING POLAR METABOLITES
OPIOID ANALGESICS

This invention relates to a composition for nasal
5 administration and more particularly to a composition for
the nasal administration of the polar metabolites of opioid
analgesics.

Opioid analgesics have a useful role in pain relief,
10 particularly for patients in the terminal stages of cancer.
Morphine is a widely used agent and can be administered via
injection as an oral controlled release formulation or by
suppository. Morphine has also been given via the nasal
route and morphine snuff was described in the last century.

15

The intranasal administration of opiates has been
discussed by Ralley (Can. J. Anaesth. 36, 5 491-493 (1989)
who suggested that morphine could be given by this route.
The route was relatively free of side effects normally
20 associated with opioids but a possible disadvantage was the
short duration of sedation which lasted only up to 60
minutes.

Nasal administration of morphine is discussed in EP
25 205282 where a sustained release effect is achieved through
the use of a cellulosic derivative that adheres to the
mucosa. A solid unit dosage form is described.

WO 8203768 describes a system for nasal drug delivery comprising morphine or its analogues having at least one phenolic hydroxy group with a non toxic nasal carrier. Ointments, gel solution or suspension salts of morphine are preferably used in the sustained release products.

It is well known that the therapeutic use of morphine gives rise to various side effects, including constipation and respiratory depression. Recently it has been disclosed that some of the metabolites of morphine, namely morphine-6-glucuronide and morphine-6-sulphate may be several times more active than the parent drug and is less likely to have the unwanted side effects (Pasternak et al (1987) Life Sciences 41, 2845; Hanna et al. (1991) Brit.J.Anaes. 66, 103; Brown et al (1985) J Pharm.Sci. 74,821). They may also have a longer biological half-life. The use of morphine-6-glucuronide as a drug substance in its own right has been discussed in the pharmaceutical and medical literature (Osborne et al (1988) Lancet April 6 p.828). Similarly, morphine-6-sulphate has been described in the literature as an analgesic agent (Brown et al Supra). However, the major problem facing delivery of these agents and polar metabolites of this and other opioid analgesics by methods other than injection, is the high water solubility of the compounds. It is unlikely that the materials will be well absorbed across mucosal surfaces, for example from the gastrointestinal tract. It is possible that the glucuronides would be absorbed from the

colon but this would only occur after the glucuronide was converted back to the parent compound by the action of the reducing conditions within the large bowel created by the microbial flora in that region. The polar nature of the compounds also means that they are likely to be poorly transported across normal mucosal surfaces such as the nasal, buccal, vaginal and rectal mucosae. However, we have now found, surprisingly, that the absorption of such polar metabolites across the nasal mucosa can be greatly increased by combination with an absorption promoting agent.

Thus the present invention provides a composition for nasal administration comprising a polar metabolite of an opioid analgesic and an absorption promoting agent. A preferred metabolite is a glucuronide, especially morphine-6-glucuronide, however glucuronides of other opioid analgesics such as codeine, levorphanol, hydromorphone, oxymorphone, nalbuphine, buprenorphine, nalorphine, hydrocodone, oxycodone and butorphanol are also suitable. A further preferred metabolite is a sulphate, especially morphine-6-sulphate but again sulphates of other opioid analgesics such as those mentioned above are also suitable.


Opioid analgesics are metabolised in the body to a variety of compounds that are more polar than morphine itself, and this is what we mean by the term metabolite as used herein. The polar nature of a compound can be

determined by measuring its partition coefficient between an aqueous buffer and an organic solvent such as octanol. The partition coefficient of morphine, expressed as a logarithm (logP) partitioned between an aqueous buffer and octanol ranges from 0.70 to 1.03 (Hansch C. and Leo A. "Substituent Constants for Correlation Analysis in Chemistry and Biology" Wiley, New York, 1979). The polar metabolites of morphine will therefore have a lower logP value than that of morphine. The major metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M-6G). Formation of the ethereal sulphates at positions 3 and 6 in the molecule may also occur. Morphine-6-sulphate which differs from morphine itself by having an ionizable group of Carbon-6 at physiological pH has been shown to be a more potent analgesic than morphine following intracerebroventricular administration in mice (Brown et al (1985) J. Pharm. Sci. 74 821). Morphine-6-sulphate and a number of its 3-O-acetyl derivatives exhibit potent antinociceptive activity in the rat when given by subcutaneous injection (Houdi, et al (1992) Pharm. Res. 9 S-103).

The structures of morphine-6-glucuronide and morphine-6-sulphate are shown below :-

5

10



morphine-6-glucuronide

morphine-6-sulphate

The absorption promoting agent should be such that it provides therapeutic levels of metabolite in the plasma with an absorption efficiency of greater than 10% and preferably greater than 30%. The absorption is measured in terms of the bioavailability, which is defined as the ratio of the quantity of metabolite appearing in the blood after intranasal administration compared to that found after intravenous administration, expressed as a percentage.

The therapeutic level of the metabolite achieved should be a plasma concentration that is at least as equipotent as the level required for the opioid analgesic for analgesic effect. For morphine, the usual therapeutic levels in plasma are from 1-500 ng/ml, and more typically 20-100 ng/ml. Data have indicated that, for example,

morphine-6-glucuronide and morphine-6-sulphate could be many times more active than morphine. Thus the required therapeutic levels of morphine-6-glucuronide and morphine-6-sulphate may be in the same range as those for morphine or they may be much lower and it is the potency that will decide the required concentration. Although more work is required in this area, morphine-6-glucuronide and morphine-6-sulphate levels may be expected to be in the region of two times less than those of morphine to give the same pain relief effect.

The composition of the invention may be used for pain relief in a variety of situations but especially to relieve chronic pain in terminal cancer patients, for acute pain, for example after dental surgery and for other post-operative pain.

The absorption promoting agent is desirably a cationic polymer, a bioadhesive agent, a surface active agent, a fatty acid, a chelating agent, a mucolytic agent, a cyclodextrin or combinations thereof or a microsphere preparation, and may be present in the composition as a solution in an aqueous medium, a dispersion in an aqueous medium, as a powder or as microspheres. The terms used here are not intended to be mutually exclusive.

Chitosan, a cationic polymer, is a preferred absorption enhancer. Chitosan is deacetylated chitin, or

poly-N-acetyl-D-glucosamine. It is available from Protan Laboratories Inc, Redmond, Washington 98052, USA and, depending on the grade selected, can be soluble in water up to pH 6.0. A 1% solution of non-water soluble chitosan (Sea Cure) may be made by making a slurry (eg 2g/100 ml) in water and adding an equal volume of organic acid (eg 100 ml of 2% acetic acid) and stirring vigorously for one hour. Water-soluble chitosan (Sea Cure⁺) may dissolve without organic or inorganic acids being present. The chitosan may also be used as chitosan microspheres.

Chitosan has previously been used to precipitate proteinaceous material, to make surgical sutures and as an immunostimulant. It has also been employed previously in oral drug formulations in order to improve the dissolution of poorly soluble drugs (Sawayanagi et al, (1983) Chem. Pharm. Bull., 31, 2062-2068) or for the sustained release of drugs (Nagai et al, Proc. Jt. US- Jpn. Semin. Adv. Chitin, Chitosan, Relat. Enzymes, 21-39. Zikakis J.P. (ed), Academic Press. Orlando (1984)) by a process of slow erosion from a hydrated compressed matrix.

Diethylaminoethyl-dextran (DEAE-dextran) is also suitable and is a polycationic derivative of dextran containing diethylaminoethyl groups coupled to the glucose residues by ether linkages. The parent dextran can have an average molecular weight of about 5,000 to 40×10^6 , but is typically about 500,000.

Further cationic polymers which may be used in the compositions of the invention include other polycationic carbohydrates such as but not limited to inorganic or organic salts of chitosan and modified forms of chitosan (especially more positively charged ones), polyaminoacids such as polylysine, polyquaternary compounds, protamine, polyamine, DEAE-imine, polyvinylpyridine, polythiodiethylaminomethylethylene (P(TDAE)), polyhistidine, DEAE-methacrylate, DEAE-acrylamide, poly-p-aminostyrene, polyoxethane, co-polymethacrylates (e.g. copolymers of HPMA, N-(2-hydroxypropyl)-methacrylamide, GAFQUAT (US Pat No 3,910,862) and polyamidoamines. The polycationic substances used in the invention typically have a molecular weight of 10 000 or more. The chitosan (or salt thereof) preferably has an intrinsic viscosity of at least 400 ml/g, more preferably at least 500, 750 or 1000 ml/g.

The concentration of the cationic polymer in a solution is preferably 0.01 to 50% w/v, more preferably 0.1 to 50% and more preferably 0.2 to 30%.

Amongst the bioadhesive agents suitable for use are included bioadhesive microspheres. Preferably the microspheres are prepared from a bio-compatible material that will gel in contact with the mucosal surface. Substantially uniform solid microspheres are preferred. Starch microspheres (crosslinked if necessary) are a preferred material. Other materials that can be used to

form microspheres include starch derivatives, modified starches such as amyloextrin, gelatin, albumin, collagen, dextran and dextran derivatives, polyvinyl alcohol, polylactide-co-glycolide, hyaluronic acid and derivatives thereof such as benzyl and ethyl esters, gellan gum and derivatives thereof such as benzyl and ethyl esters and pectin and derivatives thereof such as benzyl and ethyl esters. By the term "derivatives" we particularly mean esters and ethers of the parent compound that can be unfunctionalised or functionalised to contain, for example, ionic groupings.

Suitable starch derivatives include hydroxyethyl starch, hydroxypropyl starch, carboxymethyl starch, cationic starch, acetylated starch, phosphorylated starch, succinate derivatives of starch and grafted starches. Such starch derivatives are well known and described in the art (for example Modified Starches: Properties and Uses, O.B. Wurzburg, CRC Press Boca Raton (1986)).

20

Suitable dextran derivatives include, diethylaminoethyl-dextran (DEAE-dextran), dextran sulphate, dextran methyl-benzylamide sulphonates, dextran methyl-benzylamide carboxylates, carboxymethyl dextran, diphosphonate dextran, dextran hydrazide, palmitoyldextran and dextran phosphate.

25

Preparation of these microspheres is well described in

the pharmaceutical literature (see for example Davis et al., (Eds), *"Microspheres and Drug Therapy"*, Elsevier Biomedical Press, 1984, which is incorporated herein by reference). Emulsion and phase separation methods are both suitable. For example, albumin microspheres may be made using the water-in-oil emulsification method where a dispersion of albumin is produced in a suitable oil by homogenization techniques or stirring techniques, with the addition if necessary of small amounts of an appropriate surface active agent. The size of the microspheres is largely dictated by the speed of stirring or homogenization conditions. The agitation can be provided by a simple laboratory stirrer or by more sophisticated devices such as a microfluidizer or homogenizer. Emulsification techniques are also used to produce starch microspheres as described in GB 1 518 121 and EP 223 303 as well as for the preparation of microspheres of gelatin. Proteinaceous microspheres may also be prepared by coacervation methods such as simple or complex coacervation or by phase separation techniques using an appropriate solvent or electrolyte solution. Full details of the methods of preparing these systems can be obtained from standard text books (see for example Florence and Attwood, *Physicochemical Principles of Pharmacy* 2nd Ed., MacMillan Press, 1988, Chapter 8).

For example, microspheres were prepared as follows:

The preparation of starch microspheres using emulsification

A 10% starch gel was prepared by heating (70°C) 5 g of starch with 40 ml of water until a clear gel was formed. After cooling water was added to a volume of 50 ml. 20 ml of the starch gel was added to 100 ml of soya oil containing antioxidant and 1% v/v Span 80 and homogenised at 7000 rpm for 3 minutes. This emulsion was added to 100 ml hot (80°C) soya oil BP (containing antioxidant) and stirred at 1500 rpm while heated to 115°C over 15 minutes. The emulsion was left stirring at 115°C for 15 minutes and then rapidly cooled. 100 ml of acetone was added and the microspheres were centrifuged at 4500 rpm for 15 minutes. They were then washed with acetone and air dried. The microspheres can be separated into the desired size fraction (for example 1-10 μ m) using appropriate sieves.

Preparation of hyaluronic acid ester microspheres by solvent extraction

An emulsion was formed by mixing a 6% w/v solution of the polymer eg benzyl hyaluronic acid ester (Hyaff - 11) in dimethylsulphoxide with white mineral oil containing 0.5% Arlacel A. The inner phase was added to the outer oil phase (their respective ratio being 1 : 16 v/v) with continuous stirring for 10 minutes. (1000 rpm). Ethyl acetate, the extraction solvent, was then added to the emulsion at a ratio of 2 : 1 v/v. The extraction proceeded for 15 minutes at a stirring rate of 700 rpm until the microparticles were formed. The microsphere suspension was

filtered and extensively washed with n-hexane and dried. Drug can be incorporated into the microspheres by addition to the initial polymer solution.

5 The obtained microsphere size was 2-10 μ m.

The preparation of albumin microspheres using an emulsification technique and heat stabilisation

10 100 ml Soya oil was mixed with 1 ml of a 10% albumin solution and homogenised at 6000 rpm. The emulsion was added to 200 ml soya oil at 50 °C and stirred at 1500 rpm. The emulsion was heated to 120 °C and equilibrated for 20°C at this temperature. The microspheres were cooled to room temperature and washed with petroleum ether, followed by
15 ethanol and acetone. They were then filtered and dried. Microspheres of 1-10 μ m were obtained.

Preparation of Albumin microspheres using a coacervation technique

20 10 ml 25% HSA solution (ph=5) was stirred (500rpm) while a 30% solution of PEG was added (2.5 ml) until phase separation occurred. The system was stirred for 15 minutes before the albumin droplets was solidified by slowly heating the mixture to 90°C and keeping it at this
25 temperature for 30 minutes. Instead of heat denaturation, glutaraldehyde can be used to crosslink the albumin but this latter method seems to make the particles aggregate to a greater extent than that seen with the heat denaturation.

The microspheres were then isolated by filtration and freeze dried.

With a stirring speed of 500 rpm particles with a mean
5 size of $43 \mu\text{m} \pm 6 \mu\text{m}$ was produced.

Preparation of soluble potato starch microspheres using a
coacervation technique

15 ml 5% starch solution (pH=7) was kept at a constant
10 temperature of 70°C and stirred (500 rpm) while a 30%
solution of PEG was added (7 ml) until phase separation had
occurred, the system was stirred for further 15 minutes
before it was cooled on ice during constant stirring. The
microspheres were then isolated by filtration and freeze
15 dried.

With a stirring speed of 500 rpm particles with a mean
size of $33 \mu\text{m} \pm 10 \mu\text{m}$ was produced.

20 Preparation of gelatine microspheres using a coacervation
technique

30 ml 10% bovin gelatine (pH=8.5) was kept at a
constant temperature of 50°C and stirred (500 rpm) while a
30% solution of PEG was added (20 ml) until the
25 coacervation region was reached. To control this step a
nephelometer can be used. The mixture was cooled on ice
during constant stirring. The microspheres were isolated
by filtration and freeze dried.

With a stirring speed of 500 rpm particles with a mean size of $60 \mu\text{m} \pm 10 \mu\text{m}$ was produced.

Preparation of albumin microspheres using an emulsion technique

100 ml olive oil was mixed with 0.5-2 ml 25% HSA solution and the mixture was stirred for 15 minutes at 500-1000 rpm to form a w/o-emulsion. Solidification of the albumin droplets can be done either by the addition of 0.1-0.4 ml 25% glutaraldehyde and letting this react with the albumin for 15 minutes, or by heating the system to 90°C for 30 minutes. In either case the microspheres are isolated by filtration, washed and freeze dried.

A stirring speed of 700 rpm gives a mean particle size of $53 \mu\text{m} \pm 11 \mu\text{m}$.

Preparation of gelatine microspheres using an emulsion technique

100 ml olive oil (70°C) was mixed with 10 ml 5-10% gelatine solution and the mixture was stirred at 500-1500 rpm keeping the temperature constant at 70°C , the emulsion is stirred for 15 minutes and was then cooled on ice during constant stirring. The microspheres were isolated by filtration, washed and freeze dried.

A concentration of 10% gelatine and a stirring speed of 1000 rpm gives a mean particle size of $70 \mu\text{m} \pm 8 \mu\text{m}$.

Preparation of Chitosan microspheres

Chitosan microspheres were prepared by an emulsion technique as follows :

5 Chitosan, as for example a glutamate salt (70% degree of deacetylation), was dissolved in water to a concentration of 5% w/v. 100 ml soybean oil was mixed with 10 ml of the 5% Chitosan solution to form a water in oil emulsion. The microspheres were stabilized by adding
10 dropwise 0.1 ml of a 25% w/v glutaraldehyde solution under continual stirring for 15 minutes. The microspheres were isolated by centrifugation, washed and freeze-dried. The size of the microspheres was in the range of 10-90 μm .

15 The microspheres obtained may be sieved if necessary in order to separate out microspheres in a desired size range. Other size separation techniques (air elutriation) may also be employed. The final microspheres can be modified by chemical cross-linking or heat treatment.
20 Suitable cross-linking agents for use with starch microspheres include epichlorohydrin, terephthaloyl chloride and sodium trimetaphosphate. Suitable agents for use with albumin microspheres include aldehydes such as formaldehyde and glutaraldehyde, oxidised dextran
25 ("dextranox") and 2,3-butanediol, the latter also being suitable for use with gelatin microspheres. Agents such as N,N,N',N'-tetramethylethylenediamine can be used with dextran microspheres. The morphine metabolite can be

incorporated into the microspheres during their preparation or sorbed into/onto the system after preparation. The effectiveness of the system can be controlled by the physical nature of the microsphere matrix and, for example, the extent of cross linking.

As an added advantage the particles may have variable controlled release characteristics through modifications made to the microsphere system, for example by controlling the degree of cross-linking or by the incorporation of excipients that alter the diffusional properties of the administered drug or by using mechanisms based on ion-exchange for metabolites that are ionizable in aqueous environments. For example DEAE-dextran and chitosan are positively charged and can be used for an ion-exchange interaction with metabolites that are negatively charged. The amount of drug that can be carried by the microspheres is termed the loading capacity, which is determined by the physico-chemical properties of the drug molecule and in particular its size and affinity for the particle matrix.

Higher loading capacities are to be expected when the administered drug is incorporated into the microspheres during the actual process of microsphere manufacture. Microcapsules of a similar size, which are bioadhesive and which have controlled release properties, or any microcapsule which provide similar absorption promoting effects may also provide similar benefit as an absorption

promoting agent. These microcapsules can be produced by a variety of methods. The surface of the capsule can be adhesive in its own right or can be modified by coating methods familiar to those skilled in the art. These coating materials are preferably bioadhesive polymers such as polycarbophil, carbopol, DEAE-dextran, alginates, or chitosan. Other bioadhesive powdery materials such as microcrystalline cellulose, dextrans and polycarbophils may also be used.

10

Surface active agents which are suitable include bile salts such as sodium deoxycholate and cholylsarcosine (a synthetic N-acyl conjugate of cholic acid with sarcosine [N-methylglycine]), and derivatives such as sodium tauro dihydrofusidate, non-ionic surfactants, such as laureth-9 (polyoxyethylene -9 lauryl ether), phospholipids and lysophosphatidyl compounds such as lysolecithin, lysophosphatidyl-ethanolamine, lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylserine, lysophosphatidic acid etc. Other phospholipid compounds soluble in water can be expected to demonstrate similar effects, for example short chain phosphatidylglycerol and phosphatidylcholines. A suitable concentration is from 0.02 to 10%. Phospholipids and lysophosphatides are preferred absorption promoting materials. Lysophosphatides are produced by the hydrolysis of phospholipids. Such materials are surface active and form micellar structures.

25

Lysophosphatidylcholine, which is produced from egg or soy lecithin, changes the permeability of membranes and allows the increased uptake of proteins and peptides including, for example, insulin, human growth hormone and other products of biotechnology and recombinant DNA methodologies. After administration the lysophosphatides are converted by the cells of the endothelial lining of the mucosa to the intact phosphatides which are normal cell components. (Lysolecithin itself is also present in cell membranes in very small quantities.) This rapid and efficient conversion of lysophosphatides into the complete phosphatide structure leads to much reduced adverse reactions and side effects in terms of irritation and toxicity.

15

Other lysophosphatidylcholines that have different acyl groups as well as lyso compounds produced from phosphatidylethanolamines, phosphatidylglycerols and phosphatidic acid which have similar membrane modifying properties may be used. Water soluble phospholipids with short acyl chains will also be appropriate since these are surface active. Acyl carnitines (e.g. palmitoyl-DL carnitine-chloride) are an alternative. Other materials include acyl-carnitines, acyl glycerols, non-ionic surfactants, fatty acids and salts (see for example list in Wearnly, Crit. Rev. The. Drug Carrier Systems, 8:331-394 (1991), Table 2), glycyrrhetinates and biological detergents listed in the SIGMA catalog, 1988, page 316-321.

20
25

Also agents that modify the membrane fluidity and permeability would be appropriate such as enamines (e.g. phenylalanine enamine of ethyl-lacetoacetate), malonates, (e.g. diethyl-eneoxymethylene malonate), salicylates, bile
5 salts and analogues and fusidates. Suitable concentrations would be up to 10%.

Examples of suitable chelating agents are EGTA, EDTA and alginates. Suitable mucolytic agents include thiol-
10 containing compounds such as N-acetylcysteine and tyloxapol. Examples of suitable cyclodextrins are α -cyclodextrin, dimethyl- β -cyclodextrin, β -cyclodextrin, hydroxypopyl- β -cyclodextrin, γ -cyclodextrin, and 2-hydroxypropyl- β -cyclodextrin. Suitable peptide inhibitors
15 include actinonin, amastatin, antipain, bestatin, chloroacetyl-HO-Leu-Ala-Gly-NH₂, diprotinin A and B, ebelactone A and B, E-64, leupeptin, pepstatin A, phosphoramidon, H-Thr-(tBu)-Phe-Pro-OH, aprotinin, kallikrein, chymostatin, bensamidine, chymotrypsin,
20 trypsin. Suitable concentrations would be from 0.01 to 5%.

For morphine-6-sulphate it is also possible to use structures complementary in charge and size that will complex with the molecule and thereby facilitate uptake
25 across the nasal mucosa. Examples of suitable agents are betaines, alkyl alpha picolinium bromides, amino acids such as arginine and homoarginine hydrochlorides, labile quarternary ammonium salts, for example as described in US

4,140,796, ion-pairing agents for anionic drugs for example those described by Jonkman and Hunt, (1983) Pharm Weekblad. Sci. Ed. 5 41 and N,N,dialkylpropionamides.

5 Preferred absorption promoting agents for use with both morphine-6-sulphate and morphine-6-glucuronide are bioadhesive microspheres, especially starch microspheres, or a lysophospholipid such as lysophosphatidylglycerol. Further preferred materials for use with morphine-6-
10 glucuronide are chitosan and chelating agents such as EDTA.

Compositions according to the invention can be administered by any appropriate method according to their form. A composition comprising microspheres or a powder
15 can be administered using a nasal insufflator device. Example of these are already employed for commercial powder systems intended for nasal application (e.g. Fisons Lomudal System).

20 The insufflator produces a finely divided cloud of the dry powder or microspheres. The insufflator is preferably provided with means to ensure administration of a substantially fixed amount of the composition. The powder or microspheres may be used directly with an insufflator
25 which is provided with a bottle or container for the powder or microspheres. Alternatively the powder or microspheres may be filled into a capsule such as a gelatin capsule, or other single dose device adapted for nasal administration.

The insufflator preferably has means to break open the capsule or other device.

A composition comprising a solution or dispersion in
5 an aqueous medium can be administered as a spray using an appropriate device such as a metered dose aerosol valve or a metered dose pump. A gas or liquid propellant can be used. Details of other devices can be found in the pharmaceutical literature (see for example Bell, A.
10 Intranasal Delivery Devices, in Drug Delivery Devices Fundamentals and Applications, Tyle P. (ed), Dekker, New York, 1988), Remington's Pharmaceutical Sciences, Mack Publishing Co., 1975.

15 The invention will now be further demonstrated with reference to the following example.

Example 1

Experimental details

20 Morphine 6-glucuronide purchased from Ultrafine Chemicals, Salford, UK, was mixed in solution with the polycationic material chitosan, obtained from Protan Ltd of medium viscosity grade. The dose of morphine-6-glucuronide was 0.15 mg/kg. The chitosan concentration was 0.5%. The
25 solution was administered into the sheep nostril using a simple spray pump device followed by serial blood sampling. The appearance of the morphine-6-glucuronide in the plasma was followed by taking serial blood samples, removing the

red cells then assaying plasma samples for morphine 6-glucuronide. Control experiments were conducted using i.v. dosage of the glucuronide.

5. Dosing

Three animals (labelled NF, OF, PF) were given morphine-6-glucuronide intravenously as a bolus of 0.015 mg/kg and a further three animals (labelled IF, JF, KF) received nasally administered morphine-6-glucuronide at a dose of 0.15 mg/kg. Blood samples (10 ml) were taken at the following times.

Predose, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes.

15

Plasma was separated by centrifugation soon after sampling and the plasma samples (approximately 5 ml) were stored at -80°C prior to analysis.

20 Assay for morphine-6-glucuronide in plasma

Plasma concentrations of morphine-6-glucuronide were determined by an improved method based on the published procedure of Svennson et al (1982) J. Chromatog. Biomed. Appl. 230, 427. The method involves solid phase extraction of morphine-6-glucuronide from the plasma sample followed by high-performance liquid chromatography analysis using electrochemical detection. The limit of quantification of

the method is 1 ng/ml for a 0.5 ml plasma sample and the assay is linear over the range of 1 to 1200 ng/ml drug concentration.

- 5 During the period of analysis a seven point plasma standard calibration line (1 to 240 ng/ml) was routinely run on each day. Quality control samples consisting of sheep blank plasma spiked with known amounts of morphine-6-glucuronide were prepared in advance and stored at -20°C.
- 10 These were analysed with the study samples on each day.

Calculation of plasma concentration

- Plasma morphine-6-glucuronide concentrations were calculated by interpolation from a calibration line equation fitted by linear regression analysis. Morphine-6-glucuronide plasma concentrations of less than 1 ng/ml were regarded as not quantifiable within the limit of precision and accuracy of the assay.

20 Pharmacokinetic calculations

- The plasma concentration of morphine-6-glucuronide versus time after administration of the four formulations was characterised in terms of the maximum observed concentration (C_{max}), the time at which C_{max} occurred (T_{max}). The area under the curve (AUC) was calculated over 0-300 minutes using the linear trapezoidal method. The AUC values for the intravenous administration were normalised to the 0.15 mg/kg nasal dose for the calculation of

bioavailability. The validity of this normalisation assumes linear kinetics for morphine-6-glucuronide up to a 0.15 mg/kg intravenous dose. Clearance was calculated by dividing the dose by the AUC, and the volume of distribution was calculated by dividing the clearance by the elimination rate constant. The bioavailability was calculated by dividing the mean AUC for nasal administration by the normalised mean AUC after intravenous administration.

10

Results

Plasma-concentration time data

The plasma concentrations of morphine-6-glucuronide in the plasma samples resulting from the intravenous and nasal doses are reported in Tables 1 and 2 respectively.

No morphine was detected in any of the plasma samples (limit of detection 1 ng/ml).

Pharmacokinetic analysis

The pharmacokinetic parameters calculated from the plasma concentration data after intravenous and nasal doses are shown in Tables 3 and 4 respectively.

Bioavailability

The mean nasal bioavailability was calculated to be 32.3% (n=3).

TABLE 1
PLASMA CONCENTRATIONS AFTER INTRAVENOUS ADMINISTRATION
morphine-6-glucuronide concentration (ng/ml)

5	Time (min)	SHEEP NF	SHEEP OF	SHEEP PF
	Predose	nd	nd	nd
10	2	43.8	37.9	49.5
	5	40.3	54.7	34.6
	10	36.1	47.0	31.8
	15	28.6	37.3	28.5
	20	23.2	41.7	29.8
	30	22.5	32.1	24.3
	45	13.4	30.3	20.0
15	60	12.0	25.0	14.7
	90	9.4	17.7	11.6
	120	5.6	12.6	8.6
	150	3.5	7.3	3.5
	180	2.0	3.8	1.9
20	240	nd	1.8	1.4
	300	nd	nd	nd
	360	nd	nd	nd

TABLE 2

PLASMA CONCENTRATIONS AFTER NASAL ADMINISTRATION
morphine-6-glucuronide concentration (ng/ml)

5	Time (min)	morphine-6-glucuronide concentration (ng/ml)		
		SHEEP IF	SHEEP JF	SHEEP KF
	Predose	nd	nd	nd
	2	nd	13.3	17.1
	5	21.8	50.5	65.3
10	10	89.1	165.3	109.3
	15	121.4	154.8	110.3
	20	101.9	122.5	94.9
	30	107.2	105.5	80.9
	45	108.5	83.6	73.5
15	60	66.7	64.9	45.7
	90	41.1	41.3	29.3
	120	21.9	29.2	19.1
	150	16.0	25.9	12.7
	180	10.2	10.0	6.3
20	240	2.7	6.9	3.0
	300	nd	2.9	nd
	360	nd	nd	nd

nd = not detectable (less than 1.0 ng/ml)

TABLE 3

5 Pharmacokinetic parameters for morphine-6-glucuronide after intravenous administration to sheep

10					Area Under Curve (ng min ml ⁻¹)	Clearance (ml min ⁻¹ kg ⁻¹)	Apparent Volume of Distribution (lkg ⁻¹)
	Cmax (ng ml ⁻¹)	Tmax(min)	T1/2 (min)	Sheep Identity			
15	44	2	58	NF	2165	6.9	0.58
	55	5	53	OF	3819	3.9	0.30
	50	2	42	PF	2560	5.9	0.35
20	50	3	51	Mean	2848	5.6	0.41

TABLE 4

Pharmacokinetic parameters for morphine-6-glucuronide after nasal administration to sheep

		Cmax (ng ml ⁻¹)	Tmax(min)	T _{1/2} (min)	Area Under Curve (ng min ml ⁻¹)	Bio- availability *(ml min ⁻¹ kg ⁻¹)	Clearance *(ml min ⁻¹ kg ⁻¹)	Apparent Volume of Distribution *(lkg ⁻¹)
10								
15	Sheep Identity							
	IF	121	15	51	9382	32.9	5.3	0.37
	JF	165	10	41	10631	37.3	5.3	0.31
20	KF	110	15	42	7581	26.6	5.3	0.31
	Mean	132	13	45	9198	32.3	5.3	0.33

* values corrected for bioavailable dose

Example 2

A bioadhesive powder formulation of morphine-6-glucuronide was prepared using microspheres of cross-linked starch. The microspheres were prepared by the method
5 described in GB 1518121 or EP 223302 described above. A preferred size of microspheres is 1-100 μm .

75 mg of morphine-6-glucuronide was dissolved in 30 ml water and mixed with 1 g of starch microspheres. The
10 product was freeze-dried to produce a free flowing powder. The final concentration of morphine metabolite in the product was 0.075 mg/mg of starch microspheres.

The powder was administered to the nasal cavity using
15 an insufflator device. The quantity administered was 2.0 mg microspheres per kg body weight containing 0.15 mg morphine-6-glucuronide.

Example 3

20 A bioadhesive powder formulation of morphine-6-sulphate was prepared using microspheres of cross-linked starch. The microspheres were prepared by the method described in GB 1518121 or EP 223302 described above. A preferred size of microspheres is 1-100 μm .

25

75 mg of morphine-6-sulphate was dissolved in 30 ml water and mixed with 1 g of starch microspheres. The product was freeze-dried to produce a free flowing powder.

The final concentration of morphine metabolite in the product was 0.075 mg/mg of starch microspheres.

5 The powder was administered to the nasal cavity using an insufflator device. The quantity administered was 2.0 mg microspheres per kg body weight containing 0.15 mg morphine-6-sulphate.

Example 4

10 The bioadhesive microsphere system described in Examples 2 and 3 were prepared but in addition an absorption enhancing agent was employed. A preferred material is lysophosphatidyl glycerol (LPG). 100 mg LPG was added to the suspension of the morphine metabolite and
15 microspheres. The freeze dried product was administered as a powder as in Example 1 and 2. The final quantities of morphine-6-glucuronide or morphine-6-sulphate and enhancing agent were 7.5 mg and 10 mg, respectively in a 100 mg dose of microspheres.

20

Example 5

A liquid formulation similar to that described in Example 1 was prepared with added absorption enhancing agent as follows.

25

150 mg of morphine-6-glucuronide was dissolved in 10 ml of a 0.5% solution of medium viscosity grade of Chitosan (80% degree of deacetylation, Protan Limited). The

substituted cyclodextrin material dimethyl- β -cyclodextrin (Sigma Chemical Comp) was added to provide a concentration of 5%. The liquid formulation was administered using a conventional pump spray device.

5

Example 6

The formulation described in Example 5 was prepared but in the place of the dimethyl- β -cyclodextrin, α -cyclodextrin (Sigma Chemical Co.) at the same concentration of 50 mg/ml was added.

10

Example 7

The microsphere formulation described in Example 4 was prepared but instead of the enhancing agent a chelating agent in the form of EDTA was employed. 50 mg of EDTA was added to the suspension of morphine metabolite and microspheres. The product was freeze dried as before in Example 2. The final quantities of morphine-6-glucuronide and chelating agent are 7.5 mg and 5 mg, respectively in a 100 mg dose of microspheres administered to sheep.

15

20

CLAIMS

1. A composition for nasal administration comprising a polar metabolite of an opioid analgesic and an absorption promoting agent.
- 5 2. A composition according to claim 1 wherein the metabolite is a glucuronide.
3. A composition according to claim 1 wherein the
10 metabolite is a sulphate.
4. A composition according to claim 2 wherein the glucuronide is morphine-6-glucuronide.
- 15 5. A composition according to claim 3 wherein the sulphate is morphine-6-sulphate.
6. A composition according to any one of claims 1 to 5 wherein the absorption promoting agent is a cationic
20 polymer, a bioadhesive agent, a surface active agent, a fatty acid, a chelating agent, a mucolytic agent, a cyclodextrin, or a microsphere preparation, or combinations thereof.
- 25 7. A composition according to claim 6 wherein the absorption promoting agent is chitosan.
8. A composition according to any one of the preceding

claims wherein the composition comprises a solution or dispersion of the absorption promoting agent.

9. A composition according to any one of claims 1 to 7
5 wherein the composition comprises microspheres as the absorption promoting agent.

10. A composition substantially as described hereinbefore with reference to the examples.

10

11. A method of relieving pain comprising administering a composition according to any one of claims 1 to 10 to the nasal mucosa.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/00228

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K31/485; A61K9/00; A61K9/16; A61K47/36														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System</td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">A61K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	A61K								
Classification System	Classification Symbols													
Int.Cl. 5	A61K													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category⁹</th> <th style="width: 70%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> WO,A,8 203 768 (UNIVERSITY KENTUCKY) 11 November 1982 cited in the application see claims </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> EP,A,0 205 282 (EUROCELTIQUE) 17 December 1986 cited in the application see claims see example 1 </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;"> DE,A,3 602 370 (S.CHRUBASIK) 6 August 1987 see claims </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> </tbody> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	WO,A,8 203 768 (UNIVERSITY KENTUCKY) 11 November 1982 cited in the application see claims	1-11	A	EP,A,0 205 282 (EUROCELTIQUE) 17 December 1986 cited in the application see claims see example 1	1-11	A	DE,A,3 602 370 (S.CHRUBASIK) 6 August 1987 see claims	1-11
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
A	WO,A,8 203 768 (UNIVERSITY KENTUCKY) 11 November 1982 cited in the application see claims	1-11												
A	EP,A,0 205 282 (EUROCELTIQUE) 17 December 1986 cited in the application see claims see example 1	1-11												
A	DE,A,3 602 370 (S.CHRUBASIK) 6 August 1987 see claims	1-11												
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">23 APRIL 1993</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">12.05.93</div> </td> </tr> <tr> <td style="padding: 5px;"> International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div> </td> <td style="padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">SCARPONI U.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">23 APRIL 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">12.05.93</div>	International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">SCARPONI U.</div>								
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">23 APRIL 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">12.05.93</div>													
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">SCARPONI U.</div>													

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/00228

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
ALTHOUGH CLAIM 11 IS DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN BODY BY
THERAPY (RULE 39.1(IV)PCT) THE SEARCH HAS BEEN CARRIED OUT AND BASED UPON
THE ALLEGED EFFECTS OF THE COMPOSITIONS.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300228
SA 69547

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23/04/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8203768	11-11-82	US-A- 4464378	07-08-84
		AU-A- 8524782	24-11-82
		CA-A- 1183778	12-03-85
		EP-A- 0077393	27-04-83
EP-A-0205282	17-12-86	AU-B- 595801	12-04-90
		AU-A- 5828486	18-12-86
		CA-A- 1277913	18-12-90
		JP-A- 61286321	16-12-86
		US-A- 4940587	10-07-90
DE-A-3602370	06-08-87	None	

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82